Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

News Conference News ACC 2024

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Yael L. Maxwell

April 06, 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

March 27, 2024

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

November 13, 2023

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

News Conference News EAS 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

Michael O'Riordan

May 24, 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

News Conference News ACC 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Michael O'Riordan

April 07, 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

ApoB Gains Ground as Best Lipid Predictor of MI Risk

News Conference News AHA 2021

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Michael O'Riordan

November 22, 2021

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

November 18, 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News ESC 2016

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Michael O'Riordan

August 27, 2016

News Conference News EAS 2016

Non-HDL Cholesterol, Inflammation Appear to Be Linked in Patients Undergoing Elective PCI

Yael L. Maxwell

June 08, 2016

News Conference News ACC 2016

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Michael O'Riordan

April 03, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.